Resonance Specialities Ltd
Incorporated in 1989, Resonance Specialties Ltd manufactures Pyridine, Picoline, Cynopyridine and derivatives of the same[1]
- Market Cap ₹ 131 Cr.
- Current Price ₹ 114
- High / Low ₹ 124 / 65.0
- Stock P/E 18.5
- Book Value ₹ 55.5
- Dividend Yield 0.88 %
- ROCE 15.4 %
- ROE 11.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 6.75% over past five years.
- Company has a low return on equity of 8.78% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
45.30 | 37.84 | 38.63 | 33.91 | 35.71 | 41.40 | 56.14 | 70.29 | 75.76 | 57.98 | 54.82 | 77.81 | |
42.19 | 36.59 | 35.62 | 31.89 | 35.06 | 36.51 | 48.39 | 56.04 | 59.01 | 51.15 | 50.00 | 67.03 | |
Operating Profit | 3.11 | 1.25 | 3.01 | 2.02 | 0.65 | 4.89 | 7.75 | 14.25 | 16.75 | 6.83 | 4.82 | 10.78 |
OPM % | 6.87% | 3.30% | 7.79% | 5.96% | 1.82% | 11.81% | 13.80% | 20.27% | 22.11% | 11.78% | 8.79% | 13.85% |
-0.38 | 1.86 | 0.26 | 0.82 | 1.08 | 1.31 | 0.44 | 1.59 | 1.36 | 1.61 | 0.93 | 0.01 | |
Interest | 0.59 | 0.58 | 0.52 | 0.39 | 0.55 | 0.54 | 0.35 | 0.29 | 0.07 | 0.11 | 0.33 | 0.35 |
Depreciation | 1.10 | 1.16 | 1.12 | 1.06 | 1.15 | 0.91 | 0.92 | 0.98 | 1.75 | 1.48 | 1.46 | 1.56 |
Profit before tax | 1.04 | 1.37 | 1.63 | 1.39 | 0.03 | 4.75 | 6.92 | 14.57 | 16.29 | 6.85 | 3.96 | 8.88 |
Tax % | 0.96% | 7.30% | 27.61% | 25.90% | 2,700.00% | 32.63% | 20.38% | 27.73% | 24.06% | 27.01% | 25.00% | 26.13% |
1.03 | 1.28 | 1.19 | 1.03 | -0.77 | 3.20 | 5.51 | 10.52 | 12.36 | 5.00 | 2.97 | 6.57 | |
EPS in Rs | 0.89 | 1.11 | 1.03 | 0.89 | -0.67 | 2.77 | 4.77 | 9.11 | 10.71 | 4.33 | 2.57 | 5.69 |
Dividend Payout % | 56.02% | 45.08% | 0.00% | 0.00% | 0.00% | 0.00% | 20.94% | 10.97% | 9.34% | 23.08% | 0.00% | 17.56% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 7% |
3 Years: | 1% |
TTM: | 42% |
Compounded Profit Growth | |
---|---|
10 Years: | 31% |
5 Years: | 1% |
3 Years: | -17% |
TTM: | 139% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 19% |
3 Years: | -12% |
1 Year: | 11% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 15% |
3 Years: | 9% |
Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 |
Reserves | 9.45 | 9.95 | 11.14 | 12.42 | 11.72 | 14.93 | 18.99 | 29.13 | 40.26 | 44.15 | 45.95 | 52.48 |
3.38 | 3.12 | 1.92 | 4.07 | 3.40 | 0.00 | 0.00 | 0.72 | 0.09 | 2.29 | 4.17 | 3.31 | |
9.77 | 9.95 | 7.76 | 11.75 | 10.19 | 11.70 | 10.60 | 13.25 | 4.89 | 7.81 | 12.12 | 8.22 | |
Total Liabilities | 34.14 | 34.56 | 32.36 | 39.78 | 36.85 | 38.17 | 41.13 | 54.64 | 56.78 | 65.79 | 73.78 | 75.55 |
15.22 | 14.26 | 13.86 | 15.06 | 14.60 | 14.07 | 14.11 | 15.90 | 13.83 | 19.91 | 22.90 | 21.33 | |
CWIP | 0.03 | 0.03 | 0.13 | 0.20 | 0.60 | 0.83 | 1.84 | 0.04 | 0.44 | 0.44 | 0.32 | 0.56 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.75 | 0.12 | 0.00 | 2.81 | 0.00 |
18.89 | 20.27 | 18.37 | 24.52 | 21.65 | 23.27 | 25.08 | 37.95 | 42.39 | 45.44 | 47.75 | 53.66 | |
Total Assets | 34.14 | 34.56 | 32.36 | 39.78 | 36.85 | 38.17 | 41.13 | 54.64 | 56.78 | 65.79 | 73.78 | 75.55 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.76 | 1.11 | 3.23 | 0.56 | 2.14 | 5.27 | 1.42 | 4.28 | 13.33 | -8.37 | 4.16 | -2.51 | |
-0.07 | -0.28 | -0.82 | -2.62 | -1.11 | -0.50 | -1.82 | -1.18 | -8.80 | 3.20 | -6.63 | 2.15 | |
-0.60 | -1.52 | -2.41 | 1.76 | -1.01 | -3.65 | 1.15 | 0.31 | -1.86 | 0.93 | 0.33 | -1.20 | |
Net Cash Flow | 1.09 | -0.69 | 0.01 | -0.30 | 0.02 | 1.11 | 0.76 | 3.42 | 2.66 | -4.24 | -2.13 | -1.56 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 76.63 | 99.16 | 66.05 | 79.76 | 67.97 | 66.74 | 39.92 | 48.92 | 39.51 | 77.68 | 88.69 | 104.94 |
Inventory Days | 81.52 | 133.71 | 159.21 | 397.20 | 211.58 | 180.17 | 232.12 | 236.12 | 175.79 | 646.44 | 340.53 | 315.97 |
Days Payable | 68.68 | 116.18 | 108.07 | 262.26 | 127.21 | 138.98 | 114.32 | 120.62 | 17.35 | 137.50 | 134.00 | 65.41 |
Cash Conversion Cycle | 89.46 | 116.69 | 117.19 | 214.70 | 152.35 | 107.93 | 157.71 | 164.41 | 197.94 | 586.62 | 295.21 | 355.50 |
Working Capital Days | 83.15 | 100.80 | 91.94 | 128.09 | 114.27 | 93.19 | 81.92 | 102.61 | 143.09 | 213.91 | 227.84 | 210.86 |
ROCE % | 7.30% | 3.96% | 8.74% | 6.84% | 2.23% | 20.21% | 30.63% | 41.32% | 34.91% | 12.65% | 7.15% | 15.40% |
Documents
Announcements
-
Board Meeting Intimation for Meeting Of Board Will Be Held On Tuesday, August 5, 2025 To Consider And Approve Unaudited Financial Results For The Quarter Ended June 30, 2025.
21 Jul - Board meeting on Aug 5 to approve Q1 June 30, 2025 unaudited financial results.
-
Board Meeting Intimation for Meeting Of Board Will Be Held On Tuesday, August 5, 2025 To Consider And Approve Unaudited Financial Results For The Quarter Ended June 30, 2025.
21 Jul - Board meeting on Aug 5 to approve Q1 June 30, 2025 unaudited results; trading window closed.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
11 Jul - Notice of 36th AGM on Aug 5, 2025; Annual Report FY 2024-25 available online.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Jul - DP) Regulations, 2018 for the quarter ended June 30, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Jul - Newspaper Notice to the shareholders of the Company for dispatch of Annual Report for the financial year ended March 31, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
RSL is an integrated Product Development Company focusing on Pyridine and its derivatives. It also has expertise in organic
chemistry and expertise in catalysis.